Ajanta Pharma Buyback Announcement Fails To Cheer Investors
Take Stock Of The Week Ahead

Get all the latest Share Market trends and news to set you up for the week ahead.

Congratulations!
You have successfully subscribed.

Shares of Ajanta Pharma were down around 2% on Friday even as the company’s board approved the share buyback proposal.

What Happened: The pharma company’s board on Friday approved the buyback of 22.10 lakh shares at the price of ₹1,425 – just shy of the company’s 52-week high.

The buyback of around 2.59% of the total number of equity shares would cost the company around ₹315 crore. The number is exclusive of the buyback tax of around ₹74 crore. The company’s promoters currently hold a 66.11% stake.

See Also: Ashwath Damodaran Hits Out At Buyback Critics: Explains Why They’ve Replaced Dividends As A Mode Of Cash Return

Shares of the speciality pharmaceutical formulation company, however, dipped further on Friday after the announcement was made in the afternoon. The company reported a 16% year-over-year rise in revenue in the December quarter at ₹972 crore.

Following the results, brokerage firm ICICI Direct maintained its ‘buy’ rating for the stock with a price target of ₹1,385 – a close to 15% upside from the stock’s last closing price of ₹1,228.65.

Price Action: Ajanta Pharma shares were down 2.32% to trade at ₹1,200.15 on Friday afternoon.

Read Next: SEBI Tightens Norms For Share Buyback Through Exchanges: Here’s What’s Changed

Don't miss a beat on the share market. Get real-time updates on top stock movers and trading ideas on Benzinga India Telegram channel.

Comments
Loading...
52-week highICICI DirectpharmaPharmaceuticalShare buyback